Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses (Q40146542)

17 September 2017

title

Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses (English)

1 reference

17 September 2017

1 reference

Shah AC

1

1 reference

17 September 2017

Parker JN

2

1 reference

17 September 2017

Gillespie GY

3

1 reference

17 September 2017

Lakeman FD

4

1 reference

17 September 2017

Meleth S

5

1 reference

17 September 2017

Markert JM

6

1 reference

17 September 2017

Cassady KA

7

1 reference

17 September 2017

publication date

12 April 2007

1 reference

17 September 2017

1 reference

17 September 2017

volume

14

1 reference

17 September 2017

issue

13

1 reference

17 September 2017

page(s)

1045-1054

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5- mutants of her

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Second-site mutation outside of the U(S)10-12 domain of Deltagamma(1)34.5 herpes simplex virus 1 recombinant blocks the shutoff of protein synthesis induced by activated protein kinase R and partially restores neurovirulence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Characterization of a recombinant herpes simplex virus 1 designed to enter cells via the IL13Ralpha2 receptor of malignant glioma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Human cytomegalovirus TRS1 and IRS1 gene products block the double-stranded-RNA-activated host protein shutoff response induced by herpes simplex virus type 1 infection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Inhibition of glioma growth by tumor-specific activation of double-stranded RNA-dependent protein kinase PKR.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Tumor specific activation of PKR as a non-toxic modality of cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Deletion of the S component inverted repeat sequence c' and the nonessential genes U(S)1 through U(S)5 from the herpes simplex virus type 1 genome substantially impairs productive viral infection in cell culture and pathogenesis in the rat central n

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neuro-oncology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Intergeneric poliovirus recombinants for the treatment of malignant glioma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

The second-site mutation in the herpes simplex virus recombinants lacking the gamma134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Confidence intervals for the survival function using Cox's proportional-hazard model with covariates

1 reference

https://api.crossref.org/works/10.1038%2FSJ.GT.3302942

7 January 2021

Identifiers

DOI

10.1038/SJ.GT.3302942

1 reference

Dimensions Publication ID

17 September 2017

1048858360

0 references

1 reference